Background: Antiplatelet therapy is critical in the management of coronary artery disease.
For patients undergoing coronary artery bypass graft surgery (CABG), controversy remains …

Concern about possible hemorrhagic complications arising from use of oral antiplatelet
agents in immediate proximity to coronary artery bypass graft (CABG) surgery leads many …

OBJECTIVES The purpose of this multicentre cohort study was to examine the relationship
between antiplatelet therapy (APT) at the time of coronary artery bypass grafting (CABG) and …

OBJECTIVE: Preoperative use of clopidogrel increases the risk of bleeding, but its
postoperative use has not been studied. We studied early postoperative clopidogrel use in …

Objectives: The goal of this study was to assess the safety of early postoperative clopidogrel
in patients undergoing on‐pump and off‐pump coronary artery bypass graft (CABG) surgery …

Objective: Clopidogrel has become the standard of care to prevent thrombotic complications
following cardiological interventions, in particular intracoronary stenting. In addition, patients …

Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass
grafting (CABG) after non–ST elevation myocardial infarctions. Cardiothoracic surgeons …

OBJECTIVES Recent guidelines suggest that patients undergoing coronary artery bypass
grafting (CABG) should discontinue clopidogrel and aspirin (ASA) 5 and 2–10 days …

The management of coronary patients scheduled for a coronary artery bypass grafting
(CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has …

Dual antiplatelet therapy with both aspirin and clopidogrel is increasingly used after
coronary artery bypass grafting (CABG); however, little is known about the safety or efficacy …